Acetaminophen protects against iron-induced cardiac damage in gerbils

Annals of Clinical and Laboratory Science

Volumn 37, Issue 1, 2007, Pages 22-33

  Walker Jr , Ernest M ^a,c   Epling, Christopher P ^a   Parris, Cordel ^a   Cansino, Silvestre ^a   Ghosh, Protip ^a   Desai, Devashish H ^a   Morrison, Ryan G ^a   Wright, Gary L ^a   Wehner, Paulette ^a   Mangiarua, Elsa I ^a   Walker, Sandra M ^b   Blough, Eric R ^a  

^a MARSHALL UNIVERSITY   (United States)

^b St Mary's Medical Center Huntington   (United States)

^c MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetaminophen; Deferoxamine; Echocardiogram; Gerbils; Hemochromatosis; Iron overload

Indexed keywords

DEFERASIROX; DEFEROXAMINE MESYLATE; IRON; IRON DEXTRAN; PARACETAMOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; GERBIL; HEART DILATATION; HEART HYPERTROPHY; HEART INJURY; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART RIGHT VENTRICLE; IRON OVERLOAD; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SYSTOLE;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; ECHOCARDIOGRAPHY; GERBILLINAE; HEART DISEASES; INJECTIONS, INTRAPERITONEAL; IRON; IRON OVERLOAD; LIVER; MALE; MYOCARDIUM; ORGAN SIZE; SPECIFIC PATHOGEN-FREE ORGANISMS; SPECTROPHOTOMETRY, ATOMIC;

GERBILLINAE;

EID: 33847220794     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Walker EM Jr, Wolfe MD, Norton ML, Jones MM. Hereditary hemochromatosis. Ann Clin Lab Sci 1998;28:300-312.
2. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
3. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55-71.
4. Brandhagen DJ, Fairbanks VF, Baldus W Recognition and management of hereditary hemochromatosis. Am Fam Physician 2002;65:853-860.
5. Kontoghiorghes GJ. Effects of ICL 670 (deferasirox) on cardiac iron concentrations. Lancet 2005;366:804.
6. Hershko C. Treating iron overload: the state of the art. Semin Hematol 2005;42(Suppl 1):S2-S4.
7. Taher A. Iron overload in thalassemia and sickle cell disease. Semin Hematol 2005;42(Suppl 1):S5-S9.
8. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol 2005;42(Suppl 1):S14-S18.
9. Nichols GM, Bacon BR. Hereditary hemochromatosis: pathogenesis and clinical features of a common disease. Am J Gastroenterol 1989;84:851-862.
10. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous deferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
11. Olivieri NF, Brittenhan GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
12. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000;23:211-223.
13. Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-1190.
14. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 2002;139:50-58.
15. Del Vecchio GC, Crollo E, Schettini F, Fischer R, De Mattia D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematol 2000;104:99-102.
16. Hoffbrand AV, Al Refaie F, Davis B, Siritanakatkul N, Jackson BFA, Cochrane J, Prescott E, Wonke B. Longterm trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91:295-300.
17. Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, Giua R, Selastio AM, Suma V, De Maraco S, Semeraro F, Moscogiuri R. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica 1998;83:496-501.
18. Olivieri HF, Brittenham GM, Matsui D, Propper RL, Cooper B, Rufo RR, Nienhius AW, Anderson W, Bunn HF, Rosenthal A. Iron-chelating therapy with oral deferiprone in patients with thalassemia major. NEJM 1995;332:918-922.
19. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. NEJM 1998;339:4l7-423.
20. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101:413-415.
21. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004;83:471-473.
22. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL 670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003;43;565-572.
23. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC. Effectiveness and safety of ICL 670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003:361:1597-1602.
24. Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP. ICL670A: Preclinical profile. Adv Exp Med Biol 2002;509:185-203.
25. Sergejew T, Forgiarini P, Schnebli HP. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol 2000;110:985-992.
26. Walker EM Jr, Method of treating iron overload with acetaminophen. US Patent #6,509,380; 2002. Marshall University, Huntington, WV.
27. Rschevkin SN. The Theory of Sound (Blunn OM, Doak PE, translators), Pergamon Press, New York, 1963.
28. Weyman AE. Physical principles of ultrasound. In: ECHO Cardiography, 2nd ed (Weyman AE, Ed), Lippincott Williams and Wilkins, Philadelphia, 1994; pp 3-28.
29. Pagana KD, Pagana TJ. Ultrasound studies. In: Mosby's Manual of Diagnostic and Laboratory Tests, 1st ed (Pagana KD, Pagana TJ, Eds), Mosby, St. Louis, 1998; pp 787-791.
30. Otto CM. Principles of echocaidiogtaphic image acquisition and Doppler analysis. In: Textbook of Clinical Echocardiography (Otto, CM, Ed), Saunders, Philadelphia; 2000; pp 1-28.
31. Szpunar J. Bio-inorganic speciation analysis by hyphenated techniques. Analyst 2000;125:963-988.
32. Stone RM, Bridges KR, Libby P. Hematological and oncological disorders and cardiovascular disease. In: Heart Disease-A Textbook of Cardiovascular Medicine, 6th ed (Braunwald E, Zipes DP, Eds), Lippincott-Raven, Philadelphia, 2001; vol 2, pp 2223-2243.
33. Virmani R, Burke A, Farb A, Atkinson JB. Ch. 8. The endomyocardial biopsy. In: Cardiovascular Pathology, 2nd ed (Virmani R, Burke A, Farb A, Atkinson JB, Eds), Saunders, Philadelphia, 2001; pp 280-320.
34. Carthew P, Dorman BM, Edwards RE, Francis JE, Smith AG. A unique rodent model for both the cardiotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 1993;69:217-222.
35. Carthew P, Edwards RE, Dorman BM. Hepatic fibrosis and iron accumulation due to endotoxin-induced haemorrhage in the gerbil. J Comp Pathol 1991;104:303-311.
36. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 2002;139:50-58.
37. Carthew P, Smith AG, Hider RC, Dorman B, Edward RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94. Biometals 1994;7:267-271.
38. Yang T, Dong WQ, Kuryshev YA, Obejero-Paz C, Levy MN, Brittenham GM, Kiatchoosakun S, Kirkpatrick D, Hoit BD, Brown AM. Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med 2002;140:263-271.
39. Obejero-Paz CA, Yang, T, Dong WQ, Levy MN, Brittenham GM, Kuryshev YA, Brown AM. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med 2003;141:121-130.
40. Laurita KR, Chuck ET, Yang T, Dong WQ Kuryshev YA, Brittenham GM, Kuryshev YA, Brittenham GM, Rosenbaum DS, Brown AM. Optical mapping reveals conduction slowing and impulse block in iron-overload cardiomyopathy. J Lab Clin Med 2003;142:83-89.
41. Yang T, Brittenham GM, Dong WQ, Levy MN, Obejero-Paz CA, Kuryshev YA, Brown AM. Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003;142:332-340.
42. Jaeschke H, Knight TR, Bajt ML. The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 2003;144:279-288.
43. James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 2003;31:1499-1506.
44. Maharaj DS, Saravanan KS, Maharaj H, Mohanakumar KP, Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methylpyridinium-induced dopaminergic neurotoxicity in rats. Neurochem Int 2004;44:355-360.
45. Merrill GF, Rork TH, Spiler NM, Golfetti R. Acetaminophen and myocardial infarction in dogs. Am J Physiol Heart Circ Physiol 2004;287:H1912-H1920.
46. Chou TM, Greenspan P. Effect of acetaminophen on the myeloperoxidase- hydrogen peroxide-nitrite mediated oxidation of LDL. Biochem Biophys Acta 2002;1581:57-63.
47. Boutaud O, Aronoff DM, Richardson JH, Marnett LJ, Oates JA. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. PNAS USA 2002;99:7130-7135.
48. Nakamoto K, Kamisaki Y, Wada K, Kawasaki H, Itoh T. Protective effect of acetaminophen against acute gastric mucosal lesions induced by ischemia-reperfusion in the rat. Pharmacology 1997;54:203-210.
49. Merrill G, McConnell P, Vandyke K, Powell S. Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2001;280:H2631-H2638.
50. Golfetti R, Rork T, Merrill G. Chronically administered acetaminophen and the ischemic/reperfused myocardium. Exp Biol Med 2003;228:674-682.
51. Bizovi KE, Smilkstein MJ. Ch. 32: Acetaminophen. In: Toxicologic Emergencies, 7th ed (Hoffman RS, Nelson LS, Eds), Mcgraw-Hill, New York, 2002; pp 480-501.